Nivolumab alone or in combination with ipilimumab demonstrated encouraging activity in patients with relapsed malignant pleural mesothelioma, according to results of the randomized, phase 2 IFCT-1501 MAPS2 trial presented at the ASCO Annual Meeting
“Our findings suggest that immunotherapy may provide new hope to patients with relapsed mesothelioma,” Arnaud Scherpereel, MD, PhD, head of the pulmonary and thoracic oncology department at University Hospital of Lille in France, said in a press release. “This randomized phase 2 trial may be enough to support the use of immune checkpoint inhibitors in this setting, but it is too early to conclude whether nivolumab alone or in combination of nivolumab and ipilimumab is better.”
Malignant pleural mesothelioma is an aggressive and rare cancer typically associated with asbestos exposure. Incidence rates are increasing but outcomes remain poor. More than 50% of patients relapse within 6 months of stopping initial chemotherapy, and median survival is 13 to 15 months. No effective therapies exist for malignant pleural mesothelioma.
[Article continues at original source]
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.